A Phase 3 interventional study of Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody and Cobimetinib in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 73 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing atezolizumab in Colorectal Neoplasms — 4 open to participants now, 8 under way, 3 of them phase 3. atezolizumab · Colorectal Neoplasms.
Among the 19 studies testing atezolizumab in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2016, is one of 4 in phase 3, and was the 2nd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →4 of the 19 studies testing atezolizumab in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Brown University · Sites in United States
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in Italy
Ages 18–75
Cancer Research UK · Sites in United Kingdom
Federation Francophone de Cancerologie Digestive · Sites in France
Ages 18+
By country, each count listing its studies:
atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, atezolizumab is the treatment under test here. Read study by study →
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 5
First in 2015; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 363 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 80 across the 19 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 16th largest by enrollment of the 77 interventional ones that give a count, is one of 4 that started in 2016, is one of 15 in phase 3, and was the 92nd registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
2 of the studies testing atezolizumab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT05118724AIO-Studien-gGmbHAtezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing atezolizumab in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study compares regorafenib, a standard of care therapy in this setting, to cobimetinib plus atezolizumab and atezolizumab monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease-specific inclusion criteria:
General inclusion criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody
Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody · Drug: Cobimetinib
Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Drug: Regorafenib
Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
Overall Survival (OS)
Overall survival is defined as the time (in months) between the date of randomization and the date of death due to any cause. Participants who were not reported as having died at the date of analysis were censored at the date when they were last known to be alive. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley.
Time frame: From randomization up to death due to any cause (up to approximately 20 months)
Progression-Free Survival (PFS) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley.
Time frame: From randomization up to disease progression or death due to any cause (up to approximately 20 months)
Percentage of Participants With Investigator-Assessed Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.1
PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Objective response and its 95% CI were calculated using the Clopper-Pearson method.
Time frame: From randomization up to death due to any cause (up to approximately 20 months)
Duration of Response (DOR) According to RECIST Version 1.1
DOR is defined as the period measured from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. Median DOR was estimated using the Kaplan-Meier method, and the 95% CI was calculated using the method of Brookmeyer and Crowley.
Time frame: From first occurrence of CR or PR up to disease progression or death due to any cause (up to approximately 20 months)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Physical Functioning Sub-scale Score
The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.
Time frame: Baseline, end of the study (up to approximately 2.5 years)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life-C30 Questionnaire (EORTC QLQ-C30) Global Quality of Life Sub-scale Score at the End of the Study
The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.
Time frame: Baseline, end of the study (up to approximately 2.5 years)
Percentage of Participants With Adverse Events (AEs)
Time frame: Baseline, end of the study (up to approximately 2.5 years)
Plasma Concentration of Cobimetinib
Time frame: Predose (0 hours) and 3 to 6 hours after dose on Day 15 of Cycles 1 and 4 (1 cycle = 28 days) (up to approximately 2.5 years).
Serum Concentration of Atezolizumab
Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4; 30 minutes post-infusion on Day 1 of Cycles 1 and 4; pre-infusion (0 hours) on Day 1 of Cycle 8 and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days)
Time frame: Pre-infusion (0 hours) on Day 1 of Cycle 1 up to approximately 2.5 years. Detailed time frame is explained in the outcome measure description field.
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Time frame: Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4, 8, and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days)
A total of 490 participants were screened of whom only 363 participants were randomized.
| Milestone | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| Started | 90 | 183 | 90 |
| Received treatment (safety population) | 80 | 179 | 90 |
| Modified itt population | 57 | 125 | 61 |
| Completed | 0 | 0 | 0 |
| Not completed | 90 | 183 | 90 |
| Withdrew: Death | 62 | 136 | 72 |
| Withdrew: Withdrawal by subject | 10 | 15 | 5 |
| Withdrew: Lost to follow-up | 0 | 3 | 2 |
| Withdrew: Sponsor decision | 18 | 29 | 11 |
Overall survival is defined as the time (in months) between the date of randomization and the date of death due to any cause. Participants who were not reported as having died at the date of analysis were censored at the date when they were last known to be alive. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley.
| months | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| Overall Survival (OS) | 8.51 (6.41 to 10.71) | 8.87 (7.00 to 10.61) | 7.10 (6.05 to 10.05) |
PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Participants who did not have post-baseline information were censored at the date of randomization + 1 day. Median OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley.
| months | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| Progression-Free Survival (PFS) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 2.00 (1.87 to 3.61) | 1.91 (1.87 to 1.97) | 1.94 (1.91 to 2.10) |
PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Objective response and its 95% CI were calculated using the Clopper-Pearson method.
| percentage of participants | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| Percentage of Participants With Investigator-Assessed Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.1 | 2.2 (0.27 to 7.80) | 2.7 (0.89 to 6.26) | 2.2 (0.27 to 7.80) |
DOR is defined as the period measured from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. Median DOR was estimated using the Kaplan-Meier method, and the 95% CI was calculated using the method of Brookmeyer and Crowley.
| months | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| Duration of Response (DOR) According to RECIST Version 1.1 | 4.50 (3.61 to 5.39) | 1.97 (1.77 to 3.81) | 2.81 (1.84 to 3.78) |
The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.
| units of a scale | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| Week 3 | — | — | -1.50 ± 10.56 |
| Week 4 | -6.52 ± 13.90 | -3.92 ± 11.05 | — |
| Week 6 | — | — | -0.14 ± 12.49 |
| Week 8 | -8.97 ± 13.95 | -3.23 ± 16.15 | — |
| Week 9 | — | — | -6.67 ± 17.19 |
| Week 12 | -7.78 ± 13.57 | -5.10 ± 15.54 | -6.40 ± 16.61 |
| Week 15 | — | — | -7.08 ± 14.90 |
| Week 16 | -9.12 ± 17.10 | -5.11 ± 16.67 | — |
| Week 18 | — | — | -3.70 ± 14.95 |
| Week 20 | -7.92 ± 19.51 | -0.87 ± 14.95 | — |
| Week 21 | — | — | -8.33 ± 17.37 |
| Week 24 | -5.45 ± 9.81 | -3.00 ± 18.67 | 0.00 ± 16.87 |
| Week 27 | — | — | 0.95 ± 15.60 |
| Week 28 | -5.00 ± 9.92 | -3.16 ± 15.29 | — |
| Week 30 | — | — | -8.00 ± 20.76 |
| Week 32 | -4.67 ± 11.35 | -10.74 ± 21.10 | — |
| Week 33 | — | — | -1.67 ± 13.74 |
| Week 36 | -12.22 ± 14.25 | -1.78 ± 16.23 | 4.44 ± 15.40 |
| Week 39 | — | — | 2.22 ± 19.25 |
| Week 40 | -5.00 ± 11.39 | -0.61 ± 16.18 | — |
| Week 42 | — | — | 4.44 ± 15.40 |
| Week 44 | 1.67 ± 3.33 | 3.33 ± 16.07 | — |
| Week 45 | — | — | 4.44 ± 15.40 |
| Week 48 | -13.33 ± 6.67 | 1.82 ± 9.47 | 0.00 ± 18.86 |
| Week 51 | — | — | 0.00 ± 18.86 |
| Week 52 | -5.00 ± 6.38 | 3.64 ± 10.05 | — |
| Week 54 | — | — | 0.00 ± 18.86 |
| Week 56 | -2.22 ± 3.85 | 5.00 ± 13.69 | — |
| Week 57 | — | — | 0.00 ± 18.86 |
| Week 60 | -3.33 ± 4.71 | 2.96 ± 11.60 | 0.00 ± 18.86 |
| Week 64 | -6.67 ± 18.86 | -2.67 ± 10.11 | — |
| Week 68 | — | 0.00 ± 0.00 | — |
| Treatment Discontinuation | -17.00 ± 19.21 | -16.24 ± 23.49 | -11.79 ± 19.01 |
| Long Term Follow Up Month 3 | -22.29 ± 24.29 | -15.11 ± 16.80 | -20.00 ± 26.67 |
| Long Term Follow Up Month 6 | -14.07 ± 17.14 | -10.00 ± 14.14 | -8.00 ± 15.92 |
| Long Term Follow Up Month 30 | — | -20.00 ± NA | 13.33 ± NA |
| Long Term Follow Up Month 33 | — | -20.00 ± NA | 13.33 ± NA |
| Long Term Follow Up Month 36 | — | -20.00 ± NA | 13.33 ± NA |
The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.
| units of a scale | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| Week 3 | — | — | -1.70 ± 17.76 |
| Week 4 | -6.44 ± 18.84 | -7.00 ± 21.24 | — |
| Week 6 | — | — | -4.86 ± 17.43 |
| Week 8 | -8.05 ± 15.98 | -4.38 ± 22.58 | — |
| Week 9 | — | — | -4.84 ± 15.78 |
| Week 12 | -1.04 ± 18.60 | -4.25 ± 18.51 | -3.67 ± 15.42 |
| Week 15 | — | — | -4.69 ± 12.16 |
| Week 16 | -4.39 ± 18.08 | -1.94 ± 23.64 | — |
| Week 18 | — | — | 7.41 ± 18.37 |
| Week 20 | 0.52 ± 18.38 | 4.71 ± 23.28 | — |
| Week 21 | — | — | 6.25 ± 19.29 |
| Week 24 | -3.79 ± 20.19 | 3.75 ± 23.95 | -6.94 ± 19.31 |
| Week 27 | — | — | -2.38 ± 19.07 |
| Week 28 | -8.33 ± 17.25 | 0.00 ± 31.18 | — |
| Week 30 | — | — | 5.00 ± 15.14 |
| Week 32 | -5.00 ± 14.80 | 1.39 ± 23.79 | — |
| Week 33 | — | — | 6.25 ± 17.18 |
| Week 36 | 0.00 ± 7.45 | 5.56 ± 16.86 | 16.67 ± 25.00 |
| Week 39 | — | — | 22.22 ± 17.35 |
| Week 40 | 2.08 ± 10.49 | 11.36 ± 12.51 | — |
| Week 42 | — | — | 25.00 ± 16.67 |
| Week 44 | 0.00 ± 13.61 | 9.52 ± 15.63 | — |
| Week 45 | — | — | 19.44 ± 9.62 |
| Week 48 | -2.78 ± 4.81 | 10.61 ± 15.85 | 8.33 ± 0.00 |
| Week 51 | — | — | 8.33 ± 0.00 |
| Week 52 | 4.17 ± 15.96 | 12.12 ± 17.62 | — |
| Week 54 | — | — | 12.50 ± 5.89 |
| Week 56 | -5.56 ± 9.62 | 18.75 ± 9.71 | — |
| Week 57 | — | — | 8.33 ± 0.00 |
| Week 60 | -4.17 ± 17.68 | 16.67 ± 15.59 | 8.33 ± 0.00 |
| Week 64 | -4.17 ± 5.89 | 6.67 ± 24.58 | — |
| Week 68 | — | 0.00 ± NA | — |
| Treatment Discontinuation | -19.87 ± 23.93 | -14.27 ± 25.98 | -14.53 ± 20.48 |
| Long Term Follow-up Month 3 | -21.30 ± 28.60 | -6.11 ± 22.15 | -11.36 ± 20.16 |
| Long Term Follow-up Month 6 | -13.89 ± 19.09 | -15.83 ± 15.44 | -11.67 ± 15.14 |
| Long Term Follow-up Month 30 | — | 0.00 ± NA | 8.33 ± NA |
| Long Term Follow-up Month 33 | — | 0.00 ± NA | 8.33 ± NA |
| Long Term Follow-up Month 36 | — | 0.00 ± NA | 8.33 ± NA |
| percentage of participants | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| Serious AEs | 23.8 | 39.7 | 16.7 |
| Non-serious AEs | 97.5 | 97.8 | 93.3 |
| Nanogram/milliliter (ng/mL) | Cobimetinib + Atezolizumab |
|---|---|
| Cycle 1 Day 15 - Predose | 195 ± 190.0 |
| Cycle 1 Day 15 - Postdose | 362 ± 89.4 |
| Cycle 4 Day 15 - Predose | 94.3 ± 741.9 |
| Cycle 4 Day 15 - Postdose | 210 ± 273.4 |
Pre-infusion (0 hours) on Day 1 of Cycles 1 to 4; 30 minutes post-infusion on Day 1 of Cycles 1 and 4; pre-infusion (0 hours) on Day 1 of Cycle 8 and every 8 cycles thereafter; at treatment discontinuation; 120 days after treatment discontinuation (up to approximately 2.5 years) (1 cycle = 28 days)
| microgram/milliliter (ug/mL) | Atezolizumab | Cobimetinib + Atezolizumab |
|---|---|---|
| Cycle 1 Day 1 - Predose | NA ± NA | NA ± NA |
| Cycle 1 Day 1 - 30 min post dose | 348 ± 150.0 | 259 ± 141.0 |
| Cycle 2 Day 1 - Predose | 81.5 ± 35.7 | 68.2 ± 191.2 |
| Cycle 2 Day 1 - 30 min post dose | 56.2 ± NA | — |
| Cycle 3 Day 1 - Predose | 118 ± 45.4 | 133 ± 51.2 |
| Cycle 4 Day 1 - Predose | 146 ± 52.4 | 167 ± 48.4 |
| Cycle 4 Day 1 - 30 min post dose | 487 ± 41.5 | 415 ± 37.2 |
| Cycle 5 Day 1 - Predose | 155 ± NA | — |
| Cycle 5 Day 1 - 30 min post dose | 456 ± NA | — |
| Cycle 8 Day 1 - Predose | 138 ± 54.6 | 198 ± 52.6 |
| Cycle 16 Day 1 - Predose | 226 ± 24.4 | 264 ± NA |
| Treatment Discontinuation | 97.9 ± 114.5 | 76.6 ± 184.9 |
| Unscheduled | 0.784 ± 2159.5 | 0.539 ± NA |
| percentage of participants | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|
| Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | 43.8 | 41.3 |
Collected over From baseline to end of study (approximately 2.5 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regorafenib | 62/90 (68.9%) | 19/90 (21.1%) | 78/80 (97.5%) |
| Cobimetinib + Atezolizumab | 136/183 (74.3%) | 71/183 (38.8%) | 173/179 (96.6%) |
| Atezolizumab | 72/90 (80%) | 15/90 (16.7%) | 81/90 (90%) |
| Event | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| PYREXIAGeneral disorders | 3/80 | 12/179 | 2/90 |
| DIARRHOEAGastrointestinal disorders | 3/80 | 6/179 | 0/90 |
| ANAEMIABlood and lymphatic system disorders | 0/80 | 5/179 | 0/90 |
| ABDOMINAL PAINGastrointestinal disorders | 2/80 | 2/179 | 1/90 |
| INTESTINAL PERFORATIONGastrointestinal disorders | 2/80 | 1/179 | 0/90 |
| SEPSISInfections and infestations | 2/80 | 4/179 | 0/90 |
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 0/80 | 3/179 | 0/90 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/80 | 0/179 | 0/90 |
| LEFT VENTRICULAR DYSFUNCTIONCardiac disorders | 1/80 | 0/179 | 0/90 |
| ANAL HAEMORRHAGEGastrointestinal disorders | 1/80 | 0/179 | 0/90 |
| Event | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab |
|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 30/80 | 115/179 | 17/90 |
| PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders | 42/80 | 3/179 | 1/90 |
| FATIGUEGeneral disorders | 38/80 | 65/179 | 24/90 |
| RASHSkin and subcutaneous tissue disorders | 17/80 | 85/179 | 8/90 |
| DECREASED APPETITEMetabolism and nutrition disorders | 34/80 | 49/179 | 21/90 |
| NAUSEAGastrointestinal disorders | 12/80 | 67/179 | 19/90 |
| HYPERTENSIONVascular disorders | 25/80 | 9/179 | 4/90 |
| PYREXIAGeneral disorders | 20/80 | 53/179 | 12/90 |
| VOMITINGGastrointestinal disorders | 9/80 | 52/179 | 13/90 |
| ABDOMINAL PAINGastrointestinal disorders | 21/80 | 30/179 | 13/90 |
| Age, Continuous(Years) | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab | Total |
|---|---|---|---|---|
| Mean | 58.4 ± 10.3 | 58.0 ± 11.9 | 56.7 ± 10.2 | 57.8 ± 11.1 |
| Sex: Female, Male(Participants) | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab | Total |
|---|---|---|---|---|
| Female | 39 | 75 | 31 | 145 |
| Male | 51 | 108 | 59 | 218 |
| Ethnicity (NIH/OMB)(Participants) | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 11 | 5 | 25 |
| Not Hispanic or Latino | 77 | 166 | 82 | 325 |
| Unknown or Not Reported | 4 | 6 | 3 | 13 |
| Race (NIH/OMB)(Participants) | Regorafenib | Cobimetinib + Atezolizumab | Atezolizumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 12 | 18 | 11 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 2 |
| Black or African American | 0 | 8 | 2 | 10 |
| White | 71 | 152 | 73 | 296 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 4 | 3 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Mar 2018, 20 months.
Results were first posted in Jun 2019, 1 year 3 months after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 20 months is below that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atezolizumab · Cobimetinib